샘플 요청 목록

 카트 문의
시장보고서
상품코드
1577547

안지오텐신 전환효소(ACE) 억제제 시장

Angiotensin Converting Enzyme (ACE) Inhibitors
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 169 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

안지오텐신 전환 효소(ACE) 억제제 세계 시장은 2030년까지 35억 달러에 달할 것으로 전망

2023년 28억 달러로 추정되는 안지오텐신 전환효소(ACE) 억제제 세계 시장은 2023-2030년 분석 기간 동안 연평균 3.7% 성장하여 2030년에는 35억 달러에 달할 것으로 예상됩니다. 본 보고서에서 분석한 부문 중 하나인 고혈압 치료는 CAGR 4.1%를 기록하여 분석 기간 종료 시점에 18억 달러에 도달할 것으로 예상됩니다. 심부전 치료 분야의 성장률은 분석 기간 동안 CAGR 3.5%로 추정됩니다.

미국 시장 7억 5,160만 달러로 추정, 중국은 CAGR 7.0%로 성장 전망

미국 안지오텐신 전환효소(ACE) 억제제 시장은 2023년 7억 5,160만 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 7억 4,450만 달러의 시장 규모에 도달할 것으로 예상되며, 2023-2030년 분석 기간 동안 7.0%의 CAGR을 기록할 것으로 예측됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 1.2%와 2.8%의 CAGR을 기록할 것으로 예상됩니다. 유럽에서는 독일이 2.0%의 CAGR로 성장할 것으로 예상됩니다.

세계 안지오텐신 전환효소(ACE) 억제제 시장 - 주요 동향 및 촉진요인 요약

심혈관질환 관리에 ACE 억제제가 중요한 이유는 무엇일까?

안지오텐신 전환 효소(ACE) 억제제는 심혈관질환, 특히 고혈압과 심부전 치료의 핵심입니다. ACE 억제제는 안지오텐신 I을 혈관을 좁히는 물질인 안지오텐신 II로 전환하는 효소를 억제하는 방식으로 작용합니다. 혈관을 이완시키고 혈압을 낮춤으로써 ACE 억제제는 심장마비, 뇌졸중 및 기타 심혈관질환의 위험을 낮추며, ACE 억제제는 고혈압 및 기타 심혈관질환 환자의 1차 치료제로 처방되는 경우가 많으며, 보다 종합적인 관리를 위해 이뇨제, 칼슘 길항제 등 다른 약물과 병용하기도 합니다. ACE 억제제는 환자의 예후를 개선하고 고위험군 환자의 사망률을 낮추는 데 중요한 역할을 합니다.

ACE 억제제 시장의 주요 부문은?

일반적인 약물 종류로는 에날라프릴, 리시노프릴, 라미프릴 등이 있으며, 각각 환자의 고유한 필요와 의사의 선호도에 따라 사용되며, ACE 억제제의 용도는 주로 고혈압, 심부전, 만성 신장 질환의 치료에 중점을 두고 있으며, 당뇨병 환자의 심혈관계 합병증 예방에도 사용됩니다. ACE 억제제의 유통 경로에는 병원, 소매 약국, 온라인 플랫폼 등이 있습니다. 시장은 심혈관질환이 만연한 북미와 유럽과 같은 선진 지역에 크게 집중되어 있지만, 아시아태평양의 신흥 시장은 의료 접근성 향상과 심혈관질환률 증가로 인해 빠르게 성장하고 있습니다.

기술 혁신은 ACE 억제제 시장에 어떤 영향을 미치고 있는가?

약물 제형 및 전달 기술의 발전으로 ACE 억제제의 효능과 환자 순응도가 향상되고 있습니다. 서방형 제제는 보다 편리한 투약 스케줄을 가능하게 하고 환자의 치료 요법 순응도를 향상시킵니다. 또한, 개인 맞춤형 의료의 혁신은 의료진이 유전적 요인에 따라 ACE 억제제 치료를 맞춤화할 수 있게함으로써 보다 효과적이고 표적화된 치료를 가능하게 하고 있습니다. 또한, ACE 억제제와 다른 심혈관계 치료제의 새로운 병용요법이 임상시험에서 검토되고 있으며, 이는 치료 결과를 개선할 수 있을 것으로 기대되고 있습니다. 이러한 발전으로 ACE 억제제는 더 많은 환자들, 특히 복잡한 질환과 합병증을 가진 환자들에게 보다 접근하기 쉽고 효과적인 치료제가 되고 있습니다.

ACE 억제제 시장의 성장 동력은 무엇일까?

ACE 억제제 시장의 성장은 고혈압 및 심혈관질환의 유병률 증가, 약물전달 기술의 발전, 예방 의학에 대한 관심 증가 등 여러 가지 요인에 기인합니다. 전 세계 인구의 고령화와 만성질환의 증가로 효과적인 심혈관 치료에 대한 수요가 증가하고 있습니다. 고혈압 관리에 대한 인식이 높아지고 저렴한 가격의 ACE 억제제 제네릭이 출시되면서 시장 성장에 기여하고 있습니다. 또한, 새로운 약물 조합과 개인 맞춤형 의료 접근법에 대한 지속적인 연구는 시장에 새로운 기회를 가져와 시장 확대를 더욱 촉진하고 있습니다.

조사 대상 기업 예시(주목받는 25개 기업)

  • Accord Healthcare, Inc.
  • Apotex, Inc.
  • AstraZeneca Plc
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Pharmanovia
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 24.10.30

Global Angiotensin Converting Enzyme (ACE) Inhibitors Market to Reach US$3.5 Billion by 2030

The global market for Angiotensin Converting Enzyme (ACE) Inhibitors estimated at US$2.8 Billion in the year 2023, is expected to reach US$3.5 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2023-2030. Hypertension Treatment, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Heart Failure Treatment segment is estimated at 3.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$751.6 Million While China is Forecast to Grow at 7.0% CAGR

The Angiotensin Converting Enzyme (ACE) Inhibitors market in the U.S. is estimated at US$751.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$744.5 Million by the year 2030 trailing a CAGR of 7.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Angiotensin Converting Enzyme (ACE) Inhibitors Market - Key Trends and Drivers Summarized

Why Are ACE Inhibitors Important in Cardiovascular Disease Management?

Angiotensin Converting Enzyme (ACE) inhibitors are a cornerstone in the treatment of cardiovascular diseases, particularly hypertension and heart failure. These medications work by inhibiting the enzyme that converts angiotensin I to angiotensin II, a substance that narrows blood vessels. By relaxing blood vessels and reducing blood pressure, ACE inhibitors lower the risk of heart attacks, strokes, and other cardiovascular events. They are often prescribed as a first-line treatment for patients with high blood pressure or other cardiovascular conditions and are sometimes combined with other medications such as diuretics or calcium channel blockers for more comprehensive management. ACE inhibitors play a critical role in improving patient outcomes and reducing mortality in high-risk individuals.

What Are the Key Segments in the ACE Inhibitors Market?

Common drug classes include enalapril, lisinopril, and ramipril, each of which is used based on patient-specific needs and physician preferences. Applications of ACE inhibitors primarily focus on treating hypertension, heart failure, and chronic kidney disease, with additional uses in preventing cardiovascular complications in diabetic patients. Distribution channels for ACE inhibitors include hospitals, retail pharmacies, and online platforms. The market is heavily concentrated in developed regions such as North America and Europe, where cardiovascular diseases are prevalent, but emerging markets in Asia-Pacific are experiencing rapid growth due to increased healthcare access and rising cardiovascular disease rates.

How Are Technological Innovations Influencing the ACE Inhibitors Market?

Technological advancements in drug formulation and delivery are enhancing the efficacy and patient compliance of ACE inhibitors. Extended-release formulations allow for more convenient dosing schedules, improving patient adherence to treatment regimens. Additionally, innovations in personalized medicine are enabling healthcare providers to tailor ACE inhibitor therapies based on genetic factors, leading to more effective and targeted treatments. Clinical trials are also exploring new combinations of ACE inhibitors with other cardiovascular drugs, offering potential for enhanced therapeutic outcomes. These developments are making ACE inhibitors more accessible and effective for a wider range of patients, particularly those with complex or coexisting conditions.

What Factors Are Driving Growth in the ACE Inhibitors Market?

The growth in the ACE inhibitors market is driven by several factors, including the rising prevalence of hypertension and cardiovascular diseases, advancements in drug delivery technologies, and the increasing focus on preventive healthcare. As the global population ages and the incidence of chronic diseases rises, the demand for effective cardiovascular treatments is expanding. The growing awareness of hypertension management and the availability of affordable generic ACE inhibitors are also contributing to market growth. Additionally, ongoing research into new drug combinations and personalized medicine approaches is opening up new opportunities in the market, further driving its expansion.

Select Competitors (Total 25 Featured) -

  • Accord Healthcare, Inc.
  • Apotex, Inc.
  • AstraZeneca Plc
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Pharmanovia
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Angiotensin Converting Enzyme (ACE) Inhibitors - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Hypertension and Cardiovascular Diseases Spurs Demand for ACE Inhibitors
    • Technological Innovations in Drug Formulation Strengthen Business Case for Advanced ACE Inhibitors
    • Increasing Focus on Managing Hypertension Expands Addressable Market for ACE Inhibitors
    • Surge in Aging Population Propels Demand for Cardiovascular Treatments, Including ACE Inhibitors
    • Growing Use of ACE Inhibitors in Combination Therapies Expands Treatment Options
    • Technological Advancements in Drug Delivery Systems Enhance Patient Compliance for ACE Inhibitors
    • Rising Awareness of Preventive Healthcare Drives Adoption of ACE Inhibitors for Hypertension Management
    • Technological Innovations in Personalized Medicine Propel Growth in Cardiovascular Drug Market
    • Rising Importance of Preventing Cardiovascular Events Drives Demand for ACE Inhibitors
    • Technological Advancements in Pharmacogenomics Enhance ACE Inhibitor Efficacy
    • Growing Focus on Reducing Hospitalizations Due to Cardiovascular Diseases Propels Market Growth
    • Increasing Focus on Lifestyle Management and Preventive Care Sustains Demand for ACE Inhibitors
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hypertension Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hypertension Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Hypertension Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Heart Failure Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Heart Failure Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Heart Failure Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chronic Kidney Disorders Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chronic Kidney Disorders Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Chronic Kidney Disorders Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Treatment Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Treatment Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Treatment Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: Canada 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • JAPAN
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Japan 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • CHINA
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: China 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • EUROPE
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • FRANCE
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: France 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • GERMANY
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Germany 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Italy 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: UK 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 47: Spain Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Spain Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Spain 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 50: Russia Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Russia Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Russia 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of Europe 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 62: Australia Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Australia Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Australia 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • INDIA
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 65: India Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: India Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: India 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 68: South Korea Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: South Korea Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: South Korea 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Rest of Asia-Pacific Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Rest of Asia-Pacific 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 80: Argentina Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Argentina Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Argentina 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 83: Brazil Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Brazil Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Brazil 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 86: Mexico Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Mexico Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Mexico 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Latin America Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Latin America 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 98: Iran Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Iran Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Iran 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 101: Israel Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Israel Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Israel 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Saudi Arabia Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Saudi Arabia 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 107: UAE Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UAE Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: UAE 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Middle East Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of Middle East 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • AFRICA
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 113: Africa Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Africa Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Africa 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제